Clinical trial
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent…
NCT00024557 · INSYS Therapeutics Inc, Industry · Completed
Key facts
| NCT number | NCT00024557 |
|---|---|
| Title | Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients |
| Official title | Phase I Study to Assess the Histologic Effect and Safety of Pre-Operative and Post-Operative Infusions of IL13-PE38QQR Cytotoxin in Patients With Recurrent Resectable Supratentorial Malignant Glioma |
| Lead sponsor | INSYS Therapeutics Inc, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma, Malignant Astrocytoma |
| Intervention type | Drug, Procedure |
| Interventions | IL13-PE38QQR, targeted fusion protein therapy, surgery |
| Enrollment | 40 |
| Start date | Jun 1, 2001 |
| Primary completion | Jun 1, 2006 |
| Completion | Jul 1, 2007 |
| First posted | Sep 21, 2001 |
| Last update posted | Jun 6, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: